Literature DB >> 12529798

Botulinum toxin type B for treatment of axillar hyperhidrosis.

Dirk Dressler1, Fereshte Adib Saberi, Reiner Benecke.   

Abstract

Recently, botulinum toxin type B (BT-B) became commercially available for treatment of cervical dystonia. It is the aim of this study to explore its use for treatment of bilateral axillar hyperhydrosis (HH). For this we directly compared the antihyperhydrotic effect of BT-B (NeuroBloc)/MyoBloc) with that of botulinum toxin type A (BT-A) (Botox). 9 patients (HD group) received BT-A 100MU unilaterally and BT-B 4000MU contralaterally. 10 patients (LD group) received BT-A 100MU and BT-B 2000MU. All patients were blinded as to which preparation was used in which side. All patients except one reported excellent HH improvement in both axillae. None of the patients had residual HH on clinical examination. The duration of HH improvement until first recurrence in the HD group was 16.0 +/-4.3 weeks in the BT-A treated axillar and 16.4 +/-4.5 weeks in the BT-B treated axillae (Wilcoxon rank-sum test, p = 0.336). In the LD group it was 16.4 +/-5.3 weeks in the BT-B treated axillae and 17.1 +/-5.7 weeks in the BT-A treated axillae (Wilcoxon rank-sum test, p = 0.059). There was also no difference in the duration of HH improvement between the axillae treated with BT-B 4000MU and BT-B 2000MU (Wilcoxon rank-sum test, p = 0.712). 5 out of 9 patients in the HD group (chi-square test, p = 0.025) and 7 out of 10 patients in the LD group (chi-square test, p = 0.008) reported more application discomfort in the BT-B treated axillae. In 6 out of 9 patients in the HD group (chi-square test, p = 0.014) and in 6 out of 10 patients in the LD group (chi-square test, p = 0.014) the onset of HH improvement appeared earlier in the BT-B treated axillae. One patient in the HD group reported dryness of the mouth and eyes and accomodation difficulties.BT-B is a safe and efficient treatment for axillar HH. Doses of BT-B 2000MU per axilla seem sufficient indicating a conversion factor between BT-A and BT-B in the order of 1:20. With a conversion factor for cervical dystonia in the order of 1:40 the autonomic nervous system seems to be relatively more sensitive to BT-B than to BT-A compared with the motor system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529798     DOI: 10.1007/s00415-002-0929-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

Review 1.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

Review 2.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 3.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

4.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

5.  Botulinum toxin therapy: reduction of injection site pain by pH normalisation.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Hans Bigalke
Journal:  J Neural Transm (Vienna)       Date:  2016-03-22       Impact factor: 3.575

Review 6.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

7.  Comparing Botox and Xeomin for axillar hyperhidrosis.

Authors:  Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2010-02-09       Impact factor: 3.575

Review 8.  The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome.

Authors:  D A Glaser
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 9.  Clinical use of non-A botulinum toxins: botulinum toxin type B.

Authors:  D Dressler; R Eleopra
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

10.  Comparing the Effect of Botulinum Toxin Type B Injection at Different Dosages for Patient with Drooling due to Brain Lesion.

Authors:  Hee Dong Park; Hyo Jae Kim; Sang Jun Park; Yong Min Choi
Journal:  Ann Rehabil Med       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.